The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate

Not Applicable

Completed

• Conditions: Transurethral Prostatectomy
• Interventions: Drug: Dexmedetomidine

• Registration Number: NCT01224470
• Lead Sponsor: Yonsei University

Brief Summary

Dexmedetomidine is a new selective and potent alpha-2 agonist. It has centrally acting anesthetic properties. It has been known that intrathecal addition of alpha-2 adrenergic agents result in prolongation of the duration of the sensory and motor blockade induced by hyperbaric bupivacaine. But the effects of intravenous dexmedetomidine on the spinal block was not evaluated. The aim of study is to assess the effect of intravenous dexmedetomidine on the low-dose spinal anesthesia for the transurethral surgery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-10-19
• Study First Submitted QC: 2010-10-19
• Study First Posted: 2010-10-20
• Study Start: 2010-11
• Primary Completion: 2011-01
• Study Completion: 2011-02
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-27
• Last Update Posted: 2011-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 51

Inclusion Criteria

• ASA class I or II
• Elective transurethral prostatectomy
• aged > 20

Exclusion Criteria

• Coagulation deficiency
• infection on the back
• Congestive heart failure or arrythmia
• Chronic alcoholic disease
• Antidepressants therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
bupivacaine	Dexmedetomidine	0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
saline	Dexmedetomidine	-

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of